Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2013
At a glance
- Drugs CMP 001; CYT 005 AllQbG10; House dust mite allergy immunotherapy
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Cytos Biotechnology
- 19 Feb 2008 The expected completion date for this trial is now 1 Mar 2008.
- 14 Jun 2006 New trial record.